Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,38
KB-1,24
PKN109,35106,2-0,05
Msft2,55
IBM-0,97
DCX70,9570,980,17
PFE2,03
16.12.2017 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.12.2017
Eleven Biother (NASDAQ Cons)
Závěr k 15.12.2017 Změna (%) Změna (USD) Objem obchodů (ks)
0,6765 3,13 0,02 2 046 694
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.12.2017
Popis společnosti
Obecné informace
Název společnostiEleven Biotherapeutics Inc
TickerEBIO
Kmenové akcie:Ordinary Shares
RICEBIO.O
ISINUS2862211065
Prioritní akciePreferred Shares
Prioritní akciePreferred Shares
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 31.12.2016 34
Akcie v oběhu k 15.11.2017 31 831 995
Počet akcionářů k 31.12.2016 33
MěnaUSD
Kontaktní informace
Ulice245 1st St Ste 1800
MěstoCAMBRIDGE
PSČ02142-1292
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 174 448 550
Fax16178580911

Business Summary: Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Eleven Biotherapeutics Inc revenues decreased 99% to $425K. Net loss totaled $22.5M vs. income of $5.4M. Revenues reflect Collaboration revenue decrease from $29.2M to $0K. Net loss reflects General and Administrative - increase from $47K to $5.4M (expense), Personnel & Other Expenses in R&D increase from $1.6M to $4M (expense), Research increase of 2% to $5.2M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 16.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardDaniel Lynch592.1.20142.1.2014
President, Chief Executive Officer, DirectorStephen Hurly4820.9.201620.9.2016
Interim Chief Financial OfficerRichard Fitzgerald5413.10.201713.10.2017
Chief Scientific OfficerGlen MacDonald5720.9.201620.9.2016
Chief Development OfficerGregory Adams5620.9.201620.9.2016